Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment‐naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta‐analysis was intended to evaluate their efficacy, addressing critical gaps in clinical decision‐making. We systematically searched PubMed, Embase, and Cochrane up to January 2025 for studies (RCT/single‐arm) assessing the efficacy of BTKis in MCL patients. Among 70 studies, the pooled CR rate in the TN group was higher than that in the R/R group (76.5% vs. 43.2%). Among TN patients, the CR rate of the regimen incorporating zanubrutinib (95.2% [95% CI 0.893, 1.000]) was significantly higher than that of the regimens containing acalabrutinib or ibrutinib ( p = 0.0042). In the R/R group, the BTKi + anti‐CD20 monoclonal antibody + small‐molecular therapy group presented a better CR rate (68.3% [95% CI 0.546, 0.820]; p < 0.0001). When comparing the monotherapy efficacy of three BTKis in R/R MCL, the results indicated that acalabrutinib exhibited a higher CR rate (43.2% [95% CI 0.339, 0.525]) than zanubrutinib or ibrutinib. In addition, zanubrutinib‐based therapy exhibited a lower pooled rate of haematological toxicities compared to the other two BTKi therapies. This work resolved critical uncertainties in BTKi selection for MCL, demonstrating acalabrutinib's and zanubrutinib's first‐line potential, leading to a meaningful improvement in response rate and a manageable safety profile. Chemotherapy‐free regimen can partially overcome the traditionally unfavourable prognosis associated with R/R MCL. These results provide a roadmap for optimizing MCL therapy. Chemotherapy‐free regimens for MCL based on BTKis warrant further validation in RCTs. These findings may advocate for updated guidelines prioritizing zanubrutinib and acalabrutinib in clinical practice.
Cytomegalovirus retinitis (CMVR) causes irreversible visual loss in patients with severe cellular immunodeficiency. Among people living with human immunodeficiency virus (HIV), risk is the highest with profound CD4+ T-cell depletion and absent or ineffective antiretroviral therapy. Other susceptible groups include transplant recipients, patients receiving treatment for malignancy or targeted immunosuppression, and children with inborn errors of immunity. This narrative review connects risk assessment, diagnosis, antiviral selection, and follow-up. Dilated retinal examination and serial imaging establish lesion activity and vision threat. Ocular-fluid polymerase chain reaction supports uncertain diagnoses, but results require interpretation alongside retinal findings and prior treatment. Antiviral selection requires concurrent assessment of lesion location, diagnostic certainty, renal function, marrow reserve, and systemic cytomegalovirus (CMV) disease. Systemic valganciclovir or ganciclovir provides the treatment backbone when feasible; immediately sight-threatening lesions may require adjunctive intravitreal therapy. Resistance or toxicity can necessitate alternatives, while evidence for newer agents remains limited. Maintenance duration depends on retinal inactivity and sustained immune recovery, with less certain stopping criteria outside HIV. Surveillance should address recurrence, immune recovery uveitis, retinal detachment, macular and vascular injury, and visual dysfunction beyond central acuity. Geographically diverse studies illustrate detection gaps, although heterogeneous populations and methods limit direct comparisons of burden and treatment outcomes.